pyrazines has been researched along with Thrombosis in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, K; Gong, L; Guo, C; He, L; Li, Y; Liao, L; Ma, C; Peng, C; Wang, C; Zhang, Y; Zhou, H | 1 |
| Li, J; Lv, H; Qu, B; Yang, L; Yang, X; Yuan, L | 1 |
| Parhofer, KG | 1 |
| Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M | 1 |
| Brandl, R; Busygina, K; Deckmyn, H; Jamasbi, J; Lorenz, R; Seiler, T; Siess, W; Weber, C | 1 |
| Garcia, C; Levade, M; Payrastre, B; Series, J; Sié, P; Viaud, J; Ysebaert, L | 1 |
| Bernlochner, I; Busygina, K; Denzinger, V; Lorenz, R; Siess, W; Weber, C | 1 |
| Cai, X; Chen, P; Chen, Z; Ge, J; Hu, H; Li, K; Pan, X; Xia, L; Yang, Y; Yu, K; Zhang, J; Zhuang, J | 1 |
| Asaka, M; Fujita, N; Hashino, S; Imamura, M; Kahata, K; Kondo, T; Morita, R; Onozawa, M; Shirai, S | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| Eby, C | 1 |
| de Maat, MP; Leebeek, FW; Libourel, EJ; Sonneveld, P; van der Holt, B | 1 |
| Connolly, G | 1 |
| Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| De Nanteuil, G; Gloanec, P; Marx, I; Mennecier, P; Rupin, A; Vallez, MO; Verbeuren, TJ | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Morgan, G | 1 |
| Bohn, D; Burgey, CS; Chen, Z; Clayton, FC; Cook, JJ; Gardell, SJ; Isaacs, RC; Krueger, JA; Kuo, L; Lewis, SD; Lucas, BJ; Lyle, EA; Lyle, TA; Lynch, JJ; McMasters, DR; Miller-Stein, C; Nantermet, PG; Pal, S; Pellicore, JM; Robinson, KA; Selnick, HG; Shafer, JA; Singh, R; Stranieri, MT; Vacca, JP; Wallace, AA; Welsh, DC; White, RB; Wong, B; Yan, Y | 1 |
| Case, BL; Clare, M; Girard, TJ; Hayes, MJ; Jones, DE; Kurumbail, RG; Lachance, RM; Nicholson, NS; Parlow, JJ; South, MS; Stallings, WC; Stegeman, RA; Stevens, AM; Wood, RS | 1 |
| LaChance, RM; Nicholson, NS; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS | 1 |
| Chen, LJ; Chen, Z; Ding, S; Feng, Y; Ma, GS; Shen, CX | 1 |
| Li, H; Liu, JY; Meng, JR; Yin, WT | 1 |
| Nakano, M; Nakashima, M; Nishiyama, H; Saniabadi, AR; Takiguchi, Y; Umemura, K; Wada, K | 1 |
| Kawamura, M; Moriya, N; Terashita, Z; Tsuji, N | 1 |
| Liao, F | 1 |
| Goto, S; Handa, S; Ikeda, Y; Li, M | 1 |
| Ruan, Q; Song, J | 1 |
| Ma, HT; Ruan, CG; Wu, GX; Wu, JC | 1 |
| Liu, SY; Sylvester, DM | 1 |
6 review(s) available for pyrazines and Thrombosis
| Article | Year |
|---|---|
Topics: Aspirin; Humans; Pyrazines; Randomized Controlled Trials as Topic; Thrombosis; Treatment Outcome; Venous Thromboembolism | 2020 |
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis | 2021 |
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Animals; Arteries; B-Lymphocytes; Benzamides; Blood Platelets; Cell Differentiation; Genetic Diseases, X-Linked; Hemorrhage; Humans; Imidazoles; Mice; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans; Immunosuppressive Agents; Paraproteinemias; Protease Inhibitors; Pyrazines; Retrospective Studies; Thalidomide; Thrombosis | 2009 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Herbs of activating blood circulation to remove blood stasis.
Topics: Aged; Animals; Anticoagulants; Blood Viscosity; Cardiovascular Agents; Coronary Disease; Drugs, Chinese Herbal; Fibrinolytic Agents; Hemodynamics; Hemorheology; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Rats; Rats, Wistar; Stroke; Thrombosis | 2000 |
24 other study(ies) available for pyrazines and Thrombosis
| Article | Year |
|---|---|
Tetramethylpyrazine Protects Endothelial Injury and Antithrombosis via Antioxidant and Antiapoptosis in HUVECs and Zebrafish.
Topics: Animals; Antioxidants; Fibrinolytic Agents; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Peroxide; Ligusticum; Pyrazines; Thrombosis; Zebrafish | 2022 |
Polyurethane End-Capped by Tetramethylpyrazine-Nitrone for Promoting Endothelialization Under Oxidative Stress.
Topics: Animals; Antioxidants; Apoptosis; Biocompatible Materials; Blood Vessel Prosthesis; Cell Adhesion; Cell Proliferation; Free Radical Scavengers; Free Radicals; Human Umbilical Vein Endothelial Cells; Humans; Mice; Neuroprotective Agents; NIH 3T3 Cells; Oxidative Stress; Oxygen; Platelet Adhesiveness; Polymers; Polyurethanes; Pyrazines; Rabbits; Tensile Strength; Thrombosis; Tissue Engineering | 2019 |
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Humans; Imidazoles; Male; Middle Aged; Piperidines; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Thrombosis | 2018 |
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Blood Platelets; Humans; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thrombosis | 2019 |
Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Cell Movement; Chemokine CXCL12; Cornea; Humans; Lung; Male; Neovascularization, Pathologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Fibrosis; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Signal Transduction; Thrombosis | 2014 |
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Pyrazines; Thrombosis | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Vincristine | 2010 |
The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Risk Factors; Thrombosis | 2011 |
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome | 2010 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Biological Availability; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Dogs; Drug Evaluation; Humans; In Vitro Techniques; Inhibitory Concentration 50; Pyrazines; Pyridines; Pyrroles; Rats; Thrombin; Thrombosis | 2011 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Topics: Acetamides; Animals; Biological Availability; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Dogs; Half-Life; Humans; In Vitro Techniques; Injections, Intravenous; Macaca mulatta; Microsomes, Liver; Models, Molecular; Oxides; Pyrazines; Pyridines; Rats; Solubility; Structure-Activity Relationship; Thrombin; Thrombosis | 2003 |
Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Topics: Crystallography, X-Ray; Drug Design; Factor VIIa; Factor Xa Inhibitors; Fibrinolytic Agents; Indicators and Reagents; Models, Molecular; Molecular Conformation; Peptide Library; Prothrombin; Pyrazines; Structure-Activity Relationship; Thrombin; Thrombosis; Trypsin Inhibitors | 2003 |
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Topics: Aminobenzoates; Animals; Bleeding Time; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa Inhibitors; Fibrinolytic Agents; Forearm; Hemodynamics; Macaca fascicularis; Male; Prothrombin Time; Pyrazines; Sodium Chloride; Thrombin; Thromboplastin; Thrombosis | 2003 |
Biocompatibility of tetramethylpyrazine-eluting stents in normal porcine coronary arteries.
Topics: Animals; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Kidney; Liver; Platelet Aggregation Inhibitors; Pyrazines; Swine; Thrombosis; Time Factors; Tunica Intima | 2008 |
[Effect of tetramethylpyrazine on experimental thrombosis formation (author's transl)].
Topics: Animals; Female; Fibrinolytic Agents; Male; Platelet Aggregation; Pyrazines; Rabbits; Rats; Thrombosis | 1981 |
A chemiluminescent detection of superoxide radical produced by adherent leucocytes to the subendothelium following thrombolysis: studies with a photochemically induced thrombosis model in the guinea pig femoral artery.
Topics: Animals; Cell Adhesion; Disease Models, Animal; Endothelium, Vascular; Femoral Artery; Guinea Pigs; Imidazoles; Light; Luminescent Measurements; Male; Neutrophils; Plasminogen Activators; Pyrazines; Recombinant Proteins; Rose Bengal; Superoxides; Thrombolytic Therapy; Thrombosis | 1996 |
Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys.
Topics: Animals; Basilar Artery; Bleeding Time; Carotid Artery Thrombosis; Coronary Thrombosis; Disease Models, Animal; Dogs; Female; Guanidines; Guinea Pigs; Injections, Intravenous; Macaca fascicularis; Male; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines; Thrombosis | 1997 |
Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates.
Topics: Blood Platelets; Blood Viscosity; Collagen; Drugs, Chinese Herbal; Humans; Ligusticum; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Binding; Pyrazines; Stress, Mechanical; Thrombosis; von Willebrand Factor | 2001 |
Mechanism of ligustrazini against thrombosis.
Topics: Binding, Competitive; Blotting, Northern; Cells, Cultured; Drugs, Chinese Herbal; Electrophoretic Mobility Shift Assay; Endothelium, Vascular; Fibrinolytic Agents; Humans; NF-kappa B; Plasminogen Activator Inhibitor 1; Pyrazines; RNA, Messenger; Thrombosis | 2000 |
Inhibitory effects of tetramethylpyrazine on platelets during cardiopulmonary bypass and arterial thrombus formation in dogs.
Topics: Animals; Blood Platelets; Cardiopulmonary Bypass; Cell Adhesion Molecules; Dogs; Female; Male; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Membrane Glycoproteins; Pyrazines; Thrombosis | 1992 |
Antithrombotic/antiplatelet activity of tetramethylpyrazine.
Topics: Animals; Biological Transport, Active; Calcium Channel Blockers; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Rats; Rats, Inbred Strains; Thrombosis | 1990 |